Amplia Therapeutics Ltd has released a press release.
Preliminary Final Report - YE 31 March 2020
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis
- Quarterly Activities Report - March 2020 Qtr
- App 4C - Quarterly Cash Flow Report - March 2020 Qtr
- FDA Awards Orphan Drug Designation for Pancreatic Cancer
- Dr. John Lambert appointed as Managing Director
Later from Amplia Therapeutics
- Preliminary Toxicology Studies Support Phase1 Clinical Trial
- Entitlement Offer to Fund Phase 1 Clinical Trial
- Capital Raising - Investor Presentation
- Institutional Entitlement Offer Completed
- Nucleus Network Appointed to Conduct Phase 1 Clinical Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics